PARABO - Pain Evaluation in Radium-223 (Xofigo) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases
- Focus Therapeutic Use
- Acronyms PARABO
- Sponsors Bayer
- 29 Sep 2017 Planned number of patients changed from 300 to 350.
- 10 Jun 2017 Biomarkers information updated
- 31 Mar 2017 Planned End Date changed from 1 Dec 2019 to 30 Sep 2020.